ED-B fibronectin as a target for antibody-based cancer treatments.
about
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting propertiesThe monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanomaInsights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probeNovel ubiquitin-derived high affinity binding proteins with tumor targeting properties.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Site-specific modification of ED-B-targeting antibody using intein-fusion technology.Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritisChallenges in design and characterization of ligand-targeted drug delivery systems.Fibronectin as target for tumor therapy.Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Immunocytokines: a review of molecules in clinical development for cancer therapy.The EDA-containing cellular fibronectin induces epithelial-mesenchymal transition in lung cancer cells through integrin α9β1-mediated activation of PI3-K/AKT and Erk1/2.Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology.Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritisA Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer
P2860
Q24320137-2E1D2A49-67CE-421A-ADE1-5D0894E728B5Q25256750-5A4275E0-E8BB-4E26-8CCE-864C4532DC5DQ27347532-6887523C-B22B-4B3B-A114-0EE65434D924Q30317537-D1AA037D-1387-4CD2-B685-684676E33889Q34216877-C19BCE66-D9F4-4976-A476-DFA63A806E0AQ34253705-1D7EE33E-6376-40E6-BB46-E964066C7F62Q35158352-665E435D-4835-4454-A470-A6EB61C2C4ADQ35769069-BA3D38AB-BC0E-453D-93B8-E9EB4100F3BBQ36346851-4B12493F-AB49-40CB-819F-C830A828D558Q36354769-3FDF296D-9278-4ED8-9647-A62A490E0F39Q37446755-366DDBF9-9F1C-4392-B046-2B74CEC40316Q37453905-C9771F51-B689-4711-983C-66163330040BQ38132742-D4AB23D9-F6BC-411A-ADD3-C126F073130BQ39113174-0A676D17-8EC9-4645-B335-25AC82B1DA5EQ40024329-A1FAC1DB-1CB5-4431-8346-E4C0539BF013Q40258401-4638385B-F036-4287-B30D-9342EFBC3206Q42031689-1DB99A06-5C84-4DA8-9751-5386A940025DQ45094027-F5B63617-B5A3-469B-9440-893AEC1B881EQ56892563-F0FE2429-A7C4-400B-84F6-1B77F035AB12Q57912088-848656E5-1FDA-47E7-AA54-60115F04F5F4
P2860
ED-B fibronectin as a target for antibody-based cancer treatments.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
ED-B fibronectin as a target for antibody-based cancer treatments.
@ast
ED-B fibronectin as a target for antibody-based cancer treatments.
@en
type
label
ED-B fibronectin as a target for antibody-based cancer treatments.
@ast
ED-B fibronectin as a target for antibody-based cancer treatments.
@en
prefLabel
ED-B fibronectin as a target for antibody-based cancer treatments.
@ast
ED-B fibronectin as a target for antibody-based cancer treatments.
@en
P2860
P356
P1476
ED-B fibronectin as a target for antibody-based cancer treatments.
@en
P2093
Andreas Menrad
Hans D Menssen
P2860
P304
P356
10.1517/14728222.9.3.491
P407
P577
2005-06-01T00:00:00Z